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host lymphocytes and consistent with our recent observations in
short-term cultures (Luznik, L. et al: Blood; in press), interesting- 
ly, M~l-specific allogeneic and host CD8 + T cells, expanded from 
the mixed chimeras had a higher affinity than the T cells derived 
from the vaccinated nontransplanted mice. In conclusion, mixed 
chimerism provides an optimal platform for immunotherapy of 
solid minors not only because of allogeneic effect but also through 
augmentation f host umor-specific immunity. 
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V~ REPERTOIRE ANALYSIS OF TISSUE INFILTRATING CD8+ TCELLS 
RESPONDING TO HINOR HISTOCOHPATIBILITY ANTIGENS 
INVOLVED IN GRAFT-VERSUS-HOST DISEASE 
Friedman, T.}VI.; Castor', D.E.; ffones, S.C.; Komlgold, R. 
KCI/bmmtnology, ffefferson Medical College, Philadelphia, PA. 
Lethal graft versus-host disease (GVHD) can be induced 
between MHC-matched murine strains expressing multiple minor 
histocompatibil ity antigen (miHA) differences. In the B6-> 
BALB.B model, both CD4+ and CDS+ donor can mediate lethal 
GVHD, whereas in the B6->CXBE model (expressing a subset of 
the BALB.B miHA), only the CDS+ T ceils are lethal. CDR3-size 
spectratyping was used to analyze the CD8+ and CD4+ T cell 
responses in both BALB.B and CXBE recipients injected with B6 
CD8+ or CD4+ T cells. Spectratype analysis of the reacting CDS+ 
T ceils indicated overlapping skewing of V]31, 4, 6, 8-10 and 14 
families in both the CXBE and BALB.B recipients and unique 
skewing of the V]3 4 family in the BALB.B recipients. The react- 
ing CD4+ T cells exhibited overlapping expansion of V134, 6-10, 
and 12-14 families, but the B6->BALB.B response also appeared 
to recognize unique BALB.B-specific miHA, indicated by addi- 
tional skewing of V132 and 11. Positively-selected TCR Wo skewed 
CD4+ and CDS+ T cell subsets injected into lethally irradiated 
BALB.B recipients were capable of inducing fatal GVHD. 
BALB.B mice transplanted with non-skewed V]3 CD4+ T cells 
survived with minimal symptoms of GVHD. Here we examine the 
T cell repertoire responses involved in target issue damage. Infil- 
trating B6 host-presensitized CDS+T cells were isolated post- 
transplant from the intestines, livers and spleens of lethally irradi- 
ated CXBE and BALB.B recipients. The results indicated 
overlapping tissue skewing between the B6->BALB.B and B6- 
>CXBE combinations for V]33, 5, 6, 14, and 18 in the spleens, for 
V~5, 9 and 13 in the intestine and V]32 and 18 in the liver. To test 
the possibility that reducing T cell responses within a critical 
GVHD target issue might diminish GVHD lethality we used 
magnetic sorting to remove the intestinal infiltrate skewed V]3 
families from the transplant inoculum. Mice transplanted with 
non-skewed V[3 CDS+ T cells exhibited a two-fold increase in 
median survival time. Taken together these results suggest hat 
differential targeting of T cell responses can be exploited to help 
avoid GVHD. 
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DENDRITIC CELLS CULTURED WITH INTERFERON PLUS GM-CSF CAN 
BE USED TO ELICIT PRI-SPECIFIC CTL FOR ADOPTIVE 
IMMUNOTHERAPY 
Wang, C/; Lu, S/; KJmts, Z.R/: Sukhumalchamlra, P/; Molldrem, 
j.ff.l 1. B3lT/7~ransplant bmmmologL Box 81, M.D. AndersoT~ Cmlcer 
Ceute* , Houstol~, TX; 2.3/1. D. Amterson Crower Center, Houstou, T~. 
We sought a more efficient method to produce potent dendritic 
ceils (DCs) that could be used to elicit PR1-CTL for adoptive 
immunotherapy. Peripheral blood mononuclear cells (PBMC) 
from healthy HLA-A2+ donors were obtained by Ficoll-Hypaque 
separation and monocytes were obtained after two-hour plastic 
adherence. Monocytes were treated for seven days in RPMI medi- 
um plus 10 % human AB serum (HS) with interferon-alpha2b 
(IFN-a) at 1000 units/nil and GM-CSF at 500 units/ml (IF/GM- 
DC). On day seven, the cultures howed a mature phenotype simi- 
lar to DC grown in the same culture media with 1L-4 (1000 
units/ml) and GM-CSF (500 units/ml) (I4/GM-DC): CD83 
(41.9% vs. 39.4%), CDl lc  (90.8% vs.85.23%), CD86, (26.5% vs. 
53.88%) and CD80 (21.9% vs. 35.49%). To compare PRl-specif- 
ic CTL elicited using either DC population, IF/GM-DC and 
IL4/GM-DC were pulsed with PRI at 20 mg/ml, radiated, and 
incubated at a 1:2 ratio with autologous PBMC from HLA-A2+ 
healthy donors. On day 7, 14 and 21 the co-cultures were restimu- 
lated with PR1 pulsed DC, and IL-2 (20 IU/ml) was added the 
following day. PRI -CTL cultures from 6 donors stained with 
PRI/HLA-A2 tetramer showed 0.16% to 5.83% (mean = 1.83%) 
tetramer+ CD8+ lymphocytes from the IF/GM-DC cultures vs. 
0.04% to 7.4% (mean = 1.92%) from the I4/GM-DC cultures 
(p>0.05). IF /GM-DC induced potent PR1-C'I'L proliferation 
with a stimulation index of 2.17 compared with 0.i9 for lympho- 
cytes alone using BrdU incorporation. Mean cytotoxicity results 
from five separate donors showed peptide-specific iysis of 33.8% 
for PRl-coated T2 cells compared with 6.5% for pp65-coated T2, 
at an effector:target ratio of 20:1 by micro-cytotoxicity assay. 
These results how that IFN-a and GM-CSF can be used to elicit 
mature DC cells from PBMC that can be used to elicit PR1-CTL 
after only 21 days of culture. 
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PHASE III TRIAL WITH INFLIXIHAB/HETHYLPREDNISOLONE (HP) VS 
MP FOR THE TREATMENT OF ACUTE GVHD: PRELIMINARY FINDINGS 
Couriel, D.R.; Hicks, K.; Gimlt, S.; Ippoliti, C.; Khouvi, I.; de Lima, 
M.; Homon, E.; Coheir, A.; HosiTzg, C.; Donato, M.; A11derlini, P.; 
Molldrem, tiff.; Gajewski, J.; Champ/in, R. Blood mJd Mar'row Tram- 
pkmtation, UT MD Anderson Cancer Center, Hollstolz, T~\: 
Preclinical and human studies of acute GVHD (aGVHD) suggest 
that tumor necrosis factor-alpha (TNF a) may play an important 
pathogenic role in aGVHD. We have previously reported a high 
response rate in the treatment of steroid-refractory aGVHD with 
infliximab, a chimeric human-monse anti- TNF-a monoclonal anti- 
body. In this study, we vahiate the efficacy and toxicity of inflLximab 
in the upfront reatment of aGVHD. Methods: Single institution, 
open-label, randomized, controlled trial that compares the combina- 
tion of infliximab with MP versus MP in the upfi'ont reatment of 
grade 2 or higher aGVHD. After stratification according to donor 
type and the presence or absence of GI involvement, patients were 
randomized to receive MP (2 mg/kg/day with standardized taper) 
plus infli~mab (10 mg/kg weekly x 4 weeks) or MP alone. Results: 
The trial has currently enrolled 52 patients with an accrual goal of 
100 patients. Of 39 patients evahiable for response, the overall 
response rate of GVHD was 63% (12/19) in the MP + inflLximab arm 
and 50% (10/20) in the MP arm. CR was observed in 11/12 treated 
with MP+ inflixiInab, and all 10 responders in those receiving MP 
alone (p=NS). In the infliximab group responses were observed in 
aGVHD of the skin (n= 10) and the GI tract (n- 5). Fourteen (60%) 
patients in the MP+ inflLximab arm developed one or more bacterial, 
viral or fimgal infections compared to 12 (60%) in the NIP arm (p= 
NS). Median survival was 208 and 168 days for the MP+ infliximab 
and MP groups respectively, and no statistical differences in mortality 
have been observed between the two arms. Number and causes of 
deaths are shown in the Table. Conclusions: So tar, both the MP+ 
inflLximab and MP arms show a similar profile of efficacy, toxicity and 
relapse rate. Both arms have a comparable and relatively high preva- 
lence of infection, highlighting the need for aggressive monitoring 
and prophylaxis nthis population. This study continues accrual. 
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ENGRAFTMENT, GVHD, IMMUNE RECONSTITUTION AND SURVIVAL 
FOLLOWING CDS+ T CELL DEPLETED ALLOGENEIC PERIPHERAL 
BLOOD STEM CELL TRANSPLANTATION (PBSCT) 
Soiff'e'r, R.J.; Alyea, E.P.; Hochbevg, E.; Ho, l'~; Lee, S.; Parileh, B.; 
Fisher, D.; Amil~, ft. Dana Favber CmTce1" hlstimte, Bosto'n, }VIA. 
Partial depletion of CD8+ T cells from donor lymphocyte infu- 
sions reduces the incidence of GVHD without comprmuising 
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